Nothing Special   »   [go: up one dir, main page]

BRPI0507984A - composto ou um sal do mesmo, processo para produzir um composto, medicamento, métodos para antagonizar angiotensina ii em um mamìfero, para melhorar a resistência de insulina em um mamìfero e para prevenir ou tratar doenças circulatórias em um mamìfero, e, uso do composto - Google Patents

composto ou um sal do mesmo, processo para produzir um composto, medicamento, métodos para antagonizar angiotensina ii em um mamìfero, para melhorar a resistência de insulina em um mamìfero e para prevenir ou tratar doenças circulatórias em um mamìfero, e, uso do composto

Info

Publication number
BRPI0507984A
BRPI0507984A BRPI0507984-5A BRPI0507984A BRPI0507984A BR PI0507984 A BRPI0507984 A BR PI0507984A BR PI0507984 A BRPI0507984 A BR PI0507984A BR PI0507984 A BRPI0507984 A BR PI0507984A
Authority
BR
Brazil
Prior art keywords
compound
mammal
salt
methods
insulin resistance
Prior art date
Application number
BRPI0507984-5A
Other languages
English (en)
Inventor
Takanobu Kuroita
Hiroki Sakamoto
Mami Ojima
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34858222&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0507984(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Priority to BR122012009489A priority Critical patent/BR122012009489B8/pt
Publication of BRPI0507984A publication Critical patent/BRPI0507984A/pt
Publication of BRPI0507984B1 publication Critical patent/BRPI0507984B1/pt
Publication of BRPI0507984B8 publication Critical patent/BRPI0507984B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyrrole Compounds (AREA)

Abstract

"COMPOSTO OU UM SAL DO MESMO, PROCESSO PARA PRODUZIR UM COMPOSTO, MEDICAMENTO, MéTODOS PARA ANTAGONIZAR ANGIOTENSINA II EM UM MAMìFERO, PARA MELHORAR A RESISTêNCIA DE INSULINA EM UM MAMìFERO E PARA PREVENIR OU TRATAR DOENçAS CIRCULATóRIAS EM UM MAMìFERO, E, USO DO COMPOSTO" A presente invenção está relacionada a um composto representado pela fórmula (I) onde R¬ 1¬ é um grupo representado pelas fórmulas onde R¬ 2¬, R¬ 3¬, R¬ 4¬, R¬ 5¬, R¬ 6¬, R¬ 7¬ e R¬ 8¬ são cada um independentemente um átompo de hidrogênio ou um C~ 1~-~ 6~ alquila, ou um sal do mesmo. O composto da presente invenção é útil como um agente para profilaxia ou para tratamento de doenças circulatórias tais como hipertensão e similares, e doenças metabólicas tais como diabetes e similares.
BRPI0507984A 2004-02-25 2005-02-23 composto ou um sal do mesmo, processo para produzir um composto, medicamento, métodos para antagonizar angiotensina ii em um mamífero, para melhorar a resistência de insulina em um mamífero e para prevenir ou tratar doenças circulatórias em um mamífero, e, uso do composto BRPI0507984B8 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122012009489A BR122012009489B8 (pt) 2004-02-25 2005-02-23 processo para produzir 2-etóxi-1-{[2’-(5-oxo-4,5-diidro-1,2,4-oxadiazol-3-il)bifenil-4-il]metil}-1h-benzimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metila ou um sal do mesmo, composição farmacéutica, e, uso

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2004-048928 2004-02-25
JP2004048928 2004-02-25
US11/031,057 US7157584B2 (en) 2004-02-25 2005-01-07 Benzimidazole derivative and use thereof
US11/031,057 2005-01-07
PCT/JP2005/003422 WO2005080384A2 (en) 2004-02-25 2005-02-23 Benzimidazole derivative and use as aii receptor antagonist

Publications (3)

Publication Number Publication Date
BRPI0507984A true BRPI0507984A (pt) 2007-07-24
BRPI0507984B1 BRPI0507984B1 (pt) 2018-07-03
BRPI0507984B8 BRPI0507984B8 (pt) 2023-03-21

Family

ID=34858222

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122012009489A BR122012009489B8 (pt) 2004-02-25 2005-02-23 processo para produzir 2-etóxi-1-{[2’-(5-oxo-4,5-diidro-1,2,4-oxadiazol-3-il)bifenil-4-il]metil}-1h-benzimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metila ou um sal do mesmo, composição farmacéutica, e, uso
BRPI0507984A BRPI0507984B8 (pt) 2004-02-25 2005-02-23 composto ou um sal do mesmo, processo para produzir um composto, medicamento, métodos para antagonizar angiotensina ii em um mamífero, para melhorar a resistência de insulina em um mamífero e para prevenir ou tratar doenças circulatórias em um mamífero, e, uso do composto

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122012009489A BR122012009489B8 (pt) 2004-02-25 2005-02-23 processo para produzir 2-etóxi-1-{[2’-(5-oxo-4,5-diidro-1,2,4-oxadiazol-3-il)bifenil-4-il]metil}-1h-benzimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metila ou um sal do mesmo, composição farmacéutica, e, uso

Country Status (34)

Country Link
US (3) US7157584B2 (pt)
EP (3) EP1857457B1 (pt)
JP (2) JP4256852B2 (pt)
KR (1) KR101080029B1 (pt)
CN (2) CN100503605C (pt)
AR (2) AR047972A1 (pt)
AT (2) ATE440095T1 (pt)
AU (1) AU2005214271B8 (pt)
BE (1) BE2012C025I2 (pt)
BR (2) BR122012009489B8 (pt)
CA (1) CA2557538C (pt)
CY (5) CY1107008T1 (pt)
DE (3) DE602005002030T2 (pt)
DK (3) DK1718641T3 (pt)
ES (3) ES2331209T3 (pt)
HK (2) HK1098472A1 (pt)
HR (3) HRP20070510T3 (pt)
HU (1) HUS1200008I1 (pt)
IL (1) IL177533A (pt)
LU (1) LU91962I2 (pt)
MA (1) MA28478B1 (pt)
ME (2) ME01089B (pt)
MY (1) MY142807A (pt)
NL (1) NL300802I2 (pt)
NO (2) NO332344B1 (pt)
NZ (1) NZ549755A (pt)
PL (3) PL2119715T3 (pt)
PT (3) PT1718641E (pt)
RS (3) RS52376B (pt)
RU (2) RU2369608C2 (pt)
SI (3) SI1718641T1 (pt)
TW (1) TWI336702B (pt)
WO (1) WO2005080384A2 (pt)
ZA (1) ZA200607241B (pt)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7157584B2 (en) * 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
ES2425567T3 (es) 2004-12-24 2013-10-16 Spinifex Pharmaceuticals Pty Ltd Método de tratamiento o profilaxis
JP4465469B2 (ja) * 2005-02-21 2010-05-19 国立大学法人佐賀大学 循環器病マーカーとしてのインターロイキン１３
GEP20115138B (en) * 2005-03-30 2011-01-10 Takeda Pharmaceuticals Co Benzimidazole derivative and use as angiotensin ii antagonist
WO2007097452A1 (ja) * 2006-02-27 2007-08-30 Takeda Pharmaceutical Company Limited 医薬用ブリスターパッケージ
EP1990052B1 (en) * 2006-02-27 2012-05-16 Takeda Pharmaceutical Company Limited Pharmaceutical package comprising 2-ethoxy-1-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-1h-benzimidazole-7-carboxylic acid (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl or 2-cyclopropyl-1-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-1h-benzimidazole-7-carboxylic acid (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl and a desiccant.
AU2007229322B2 (en) * 2006-03-20 2012-04-05 Novartis Ag Method of treatment or prophylaxis inflammatory pain
ATE552818T1 (de) * 2006-09-25 2012-04-15 Takeda Pharmaceutical Medizinische verpackung
NZ579851A (en) * 2007-03-28 2012-02-24 Takeda Pharmaceutical Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a ph control agent
JP2009062296A (ja) * 2007-09-05 2009-03-26 Fujifilm Corp カルボン酸エステル化合物の製造方法
JP5554699B2 (ja) * 2008-03-13 2014-07-23 第一三共株式会社 オルメサルタンメドキソミルを含む製剤の溶出性の改善
TW201008915A (en) * 2008-07-31 2010-03-01 Takeda Pharmaceutical Solid pharmaceutical composition
UY32126A (es) 2008-09-25 2010-04-30 Takeda Pharmaceutical Composición farmacéutica sólida
MX2011004258A (es) * 2008-10-22 2011-06-01 Merck Sharp & Dohme Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos.
US9387249B2 (en) 2008-12-23 2016-07-12 Takeda Pharmaceutical Company Limited Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone
US20110009347A1 (en) * 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
EA022365B1 (ru) 2010-05-11 2015-12-30 Янссен Фармацевтика Нв Фармацевтические композиции, содержащие производные 1-(бета-d-глюкопиранозил)-2-тиенилметилбензола как ингибиторы нзпг
WO2012090043A1 (en) 2010-12-29 2012-07-05 Jubilant Life Sciences Limited Novel solid state forms of azilsartan medoxomil and preparation thereof
BR112013017982A2 (pt) 2011-01-20 2020-10-27 Jiangsu Hansoh Pharmaceutical Co., Ltd. sais orgânicos de amina de azilsartan, processo de preparação e uso dos mesmos
CA2840818C (en) 2011-02-08 2018-12-11 Jubilant Life Sciences Limited An improved process for the preparation of azilsartan medoxomil
CN102138899B (zh) * 2011-03-18 2013-08-21 海南本创医药科技有限公司 阿齐沙坦酯脂质体固体制剂
RS55056B1 (sr) 2011-04-13 2016-12-30 Janssen Pharmaceutica Nv Proces za pripremu jedinjenja koja su korisna kao inhibitori sglt2
CN102827153B (zh) * 2011-06-14 2016-10-05 江苏豪森药业集团有限公司 阿齐沙坦的晶型及其制备方法
CN102351853B (zh) * 2011-08-29 2014-03-12 石药集团欧意药业有限公司 一种阿齐沙坦酯化合物、制备方法及其药物组合物
WO2013042067A1 (en) 2011-09-20 2013-03-28 Ranbaxy Laboratories Limited Process for the preparation of potassium salt of azilsartan medoxomil
WO2013042066A1 (en) 2011-09-20 2013-03-28 Ranbaxy Laboratories Limited Process for the preparation of azilsartan medoxomil
WO2013088384A2 (en) 2011-12-15 2013-06-20 Jubilant Life Sciences Limited Solid state forms of azilsartan and azilsartan medoxomil monopotassium and preparation thereof
AP2014007766A0 (en) 2011-12-15 2014-07-31 Takeda Pharmaceuticals Usa Inc Combination os azilsartan and chlorthlidone for treating hypertension black patients
CN104039779B (zh) * 2012-01-14 2016-08-24 广东东阳光药业有限公司 阿齐沙坦酯钾的晶型及其制备方法及其用途
WO2013114305A1 (en) * 2012-02-02 2013-08-08 Ranbaxy Laboratories Limited Process for the preparation of azilsartan medoxomil or pharmaceutically acceptable salts thereof
WO2013124748A1 (en) * 2012-02-20 2013-08-29 Alembic Pharmaceuticals Limited Novel polymorphs of azilsartan medoxomil potassium
CZ2012274A3 (cs) * 2012-04-19 2013-10-30 Zentiva, K.S. Zpusob prípravy vysoce cisté draselné soli azilsartanu medoxomilu
WO2013186792A2 (en) * 2012-06-11 2013-12-19 Msn Laboratories Limited Process for the preparation of (5-methyl-2-oxo-l,3-dioxoi-4-vl)methvl 2- ethoxv-l-{[2'-(5-oxo-4,5-dihvdro-l,2,4-oxadiazol-3-vl)biphenyi-4-vl]methyl}- lh-benzimidazole-7-carboxyiate and its salts
US20150291574A1 (en) * 2012-07-09 2015-10-15 Bandi Parthasaradhi Reddy Novel polymorphs of azilsartan
WO2014020381A1 (en) * 2012-08-01 2014-02-06 Alembic Pharmaceuticals Limited Novel crystalline form of azilsartan medoxomil potassium
WO2014033740A1 (en) 2012-08-27 2014-03-06 Hetero Research Foundation Novel polymorphs of azilsartan medoxomil
WO2014049512A2 (en) 2012-09-26 2014-04-03 Lupin Limited Novel process for preparation of azilsartan medoxomil
CZ305318B6 (cs) * 2012-09-26 2015-07-29 Zentiva, K.S. Způsob přípravy vysoce čisté draselné soli azilsartanu medoxomilu
CN105237527B (zh) * 2012-09-28 2018-03-06 武汉朗来科技发展有限公司 苯并咪唑衍生物及其制备方法和医药用途
IN2015DN03071A (pt) * 2012-10-09 2015-10-02 Avery Dennison Corp
CN103910720A (zh) * 2013-01-07 2014-07-09 广东东阳光药业有限公司 阿齐沙坦酯的新晶型及其制备方法
CN105153141B (zh) * 2013-02-04 2018-09-25 武汉朗来科技发展有限公司 苯并咪唑衍生物及其制备方法和医药用途
JP6281735B2 (ja) * 2013-03-19 2018-02-21 トーアエイヨー株式会社 急性心不全治療薬の評価方法、及び、急性心不全モデルの作製方法
RU2535005C1 (ru) * 2013-06-11 2014-12-10 Николай Андреевич Козлов Способ лечения грыж межпозвонковых дисков у собак
RU2535004C1 (ru) * 2013-06-11 2014-12-10 Николай Андреевич Козлов Способ лечения грыж межпозвонковых дисков у собак
WO2015051546A1 (zh) * 2013-10-12 2015-04-16 杭州领业医药科技有限公司 阿齐沙坦酯的晶型及其制备方法
CN105949182B (zh) * 2013-10-12 2019-03-19 杭州领业医药科技有限公司 阿齐沙坦酯的晶型及其制备方法
CN104774196B (zh) * 2014-01-09 2017-11-10 武汉朗来科技发展有限公司 一种苯并咪唑衍生物的制备方法
CN104774197B (zh) * 2014-01-09 2017-11-17 武汉朗来科技发展有限公司 一种苯并咪唑衍生物的制备方法
CN105079815A (zh) * 2014-04-30 2015-11-25 广东东阳光药业有限公司 一种阿齐沙坦酯钾组合物及其制备方法
CN104016974A (zh) * 2014-06-24 2014-09-03 浙江天宇药业股份有限公司 阿齐沙坦酯中间体及其合成方法、阿齐沙坦酯的合成方法
CZ2014702A3 (cs) 2014-10-15 2016-04-27 Zentiva, K.S. Způsob přípravy vysoce čistého azilsartanu
CN105622595A (zh) * 2014-11-21 2016-06-01 重庆朗天制药有限公司 一种阿奇沙坦酯钾盐及其中间体新的制备方法
CN105753854A (zh) * 2014-12-16 2016-07-13 重庆朗天制药有限公司 一种阿齐沙坦酯钾盐的新制备方法
US9708306B2 (en) 2015-03-18 2017-07-18 Wuhan Ll Science And Technology Development Co., Ltd Benzimidazole derivatives and preparation process and pharmaceutical uses thereof
CN106032378B (zh) * 2015-03-20 2019-10-25 武汉启瑞药业有限公司 新型arb化合物及其用途
CN104803998B (zh) * 2015-03-26 2017-08-25 晋江市托美汀生物科技有限公司 一种降低杂质含量的方法
CA2992796A1 (en) * 2015-07-29 2017-02-02 Takeda Gmbh Pde4 inhibitor for the treatment of diabetic nephropathy
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
JP6856365B2 (ja) * 2016-11-30 2021-04-07 株式会社トクヤマ アジルサルタンの製造方法
CN109071519A (zh) * 2016-01-28 2018-12-21 株式会社德山 阿齐沙坦及其制造方法
CN105628824B (zh) * 2016-03-06 2017-10-17 江苏正大清江制药有限公司 一种高效液相色谱法测定阿齐沙坦原料中有关物质的方法
CN107400122B (zh) * 2016-05-20 2020-10-23 武汉朗来科技发展有限公司 化合物及其制备方法、组合物和应用
CN105770876B (zh) * 2016-05-30 2019-09-10 广东天普生化医药股份有限公司 乌司他丁在制备治疗慢性前列腺炎药物中的用途
RU2623082C1 (ru) * 2016-07-11 2017-06-21 Государственное бюджетное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ коррекции артериальной ригидности у больных ревматоидным артритом
CN107602546B (zh) * 2016-07-11 2022-04-22 武汉朗来科技发展有限公司 化合物的晶型及其制备方法、组合物和应用
RU2634272C1 (ru) * 2016-08-10 2017-10-24 Закрытое акционерное общество "Санкт-Петербургский институт фармации" Композиция с дезамино-аргинин-вазотоцином для парентерального введения и способ её получения
CN106074416A (zh) * 2016-08-30 2016-11-09 佛山市弘泰药物研发有限公司 一种阿齐沙坦酯钾盐分散片的制备方法
US11096928B2 (en) * 2016-10-08 2021-08-24 Wuhan Ll Science And Technology Development Co., Ltd. Pharmaceutical composition
WO2019130277A1 (en) 2017-12-30 2019-07-04 Lupin Limited Pharmaceutical formulations of azilsartan medoxomil
CN110237071B (zh) * 2018-03-09 2022-03-22 武汉朗来科技发展有限公司 药物制剂及其应用
CN110237072B (zh) * 2018-03-09 2022-03-25 武汉朗来科技发展有限公司 药物组合物的制备方法
CN112567469B (zh) * 2018-06-14 2023-11-07 阿斯利康(英国)有限公司 用血管紧张素ii受体阻滞剂医药组合物治疗高血压的方法
CN112955965B (zh) * 2018-06-14 2024-04-09 阿斯利康(英国)有限公司 使用二氢吡啶类钙通道阻断剂医药组合物降低血压的方法
KR20200057662A (ko) 2018-11-16 2020-05-26 엠에프씨 주식회사 아질사르탄 유도체 화합물, 이의 중간체, 이의 제조방법 및 이를 포함하는 조성물
JP7573272B2 (ja) 2019-02-15 2024-10-25 国立大学法人東北大学 １，３－ジオキソラン誘導体
KR102220011B1 (ko) 2020-05-15 2021-02-25 대봉엘에스 주식회사 친환경 용매를 이용한 아질사탄의 제조방법 및 이에 관한 핵심 중간체 화합물
CN113912580B (zh) * 2021-11-03 2023-06-02 瑞孚信江苏药业股份有限公司 一种纯化4-(羟甲基)-5-甲基-[1,3]二氧杂环戊烯-2-酮的方法
CA3231724A1 (en) 2021-12-28 2023-07-06 Alchemedicine, Inc. Compound, angiotensin ii type 1 receptor antagonist and pharmaceutical composition
KR20240039252A (ko) 2022-09-19 2024-03-26 대봉엘에스 주식회사 안지오텐신 ⅱ 길항제로서의 아질사르탄 디시클로헥실아민 및 이를 유효성분으로 하는 심혈관질환 치료 또는 예방용 약학적 조성물
CN118059247A (zh) * 2022-11-24 2024-05-24 上海云晟研新生物科技有限公司 包含美阿沙坦钾与钙通道阻滞剂的药物组合物，及其制备方法及应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62290071A (ja) 1986-06-09 1987-12-16 Matsushita Electric Ind Co Ltd 有機電解質二次電池
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
IE920540A1 (en) 1991-02-21 1992-08-26 Sankyo Co 1-biphenylmethylimidazole derivatives, their preparation and¹their therapetuic use
US5616599A (en) 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
IL102183A (en) 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them
RU2117668C1 (ru) * 1991-10-23 1998-08-20 Эйсаи Ко., Лтд. Производное оксазолидона или его фармакологически приемлемые соли, фармацевтическая композиция, способ лечения
US5310929A (en) 1992-08-06 1994-05-10 E. I. Du Pont De Nemours And Company Prodrugs of imidazole carboxylic acids as angiotensin II receptor antagonists
US5605919A (en) * 1993-02-26 1997-02-25 Takeda Chemical Industries, Ltd. Treatment for viral diseases
TW403748B (en) * 1994-11-02 2000-09-01 Takeda Chemical Industries Ltd An oxazolidinedione derivative, its production and a pharmaceutical composition for lowering blood sugar and lipid in blood comprising the same
US5610314A (en) 1995-04-03 1997-03-11 Bristol-Myers Squibb Company Process for preparing dioxolenone derivatives used for making prodrug esters and intermediates
AU2001269516B2 (en) 2000-07-13 2006-09-14 Takeda Pharmaceutical Company Limited Lipid-rich plaque regressing agents
WO2003047573A1 (fr) 2001-12-03 2003-06-12 Takeda Chemical Industries, Ltd. Agents pour améliorer l'état de résistance à l'insuline
CN1615305A (zh) 2002-01-11 2005-05-11 武田药品工业株式会社 香豆素衍生物、生产它们的方法及其用途
EP1564213A4 (en) 2002-11-22 2009-05-27 Takeda Pharmaceutical IMIDAZOLE DERIVATIVES, PROCESS FOR THE PRODUCTION AND USE THEREOF
US6972258B2 (en) * 2003-08-04 2005-12-06 Taiwan Semiconductor Manufacturing Co., Ltd. Method for selectively controlling damascene CD bias
US7157584B2 (en) * 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
JP4364171B2 (ja) 2005-07-15 2009-11-11 本田技研工業株式会社 自動車用ドアチェッカ
UA58542U (ru) * 2010-12-16 2011-04-11 Леонид Борисович Борейко Способ фиксирования эвакуационной машины во время вытягивания застрявшей тяжелой машины

Also Published As

Publication number Publication date
DE602005002030T2 (de) 2008-05-08
DK2119715T3 (da) 2012-09-10
EP2119715A1 (en) 2009-11-18
HK1098472A1 (en) 2007-07-20
ES2331209T3 (es) 2009-12-23
AR047972A1 (es) 2006-03-15
CA2557538C (en) 2010-08-17
NO332344B1 (no) 2012-09-03
DE602005002030D1 (de) 2007-09-27
ATE370136T1 (de) 2007-09-15
HUS1200008I1 (hu) 2017-06-28
DK1857457T3 (da) 2009-12-21
SI2119715T1 (sl) 2012-10-30
RU2369608C2 (ru) 2009-10-10
NO2012017I2 (no) 2012-11-09
DE602005016162D1 (de) 2009-10-01
DE122012000018I1 (de) 2012-06-06
EP1857457A3 (en) 2007-12-05
US20060281795A1 (en) 2006-12-14
RS50537B (sr) 2010-05-07
AR094588A2 (es) 2015-08-12
NL300802I2 (pt) 2016-05-18
EP2119715B1 (en) 2012-05-30
ES2388945T3 (es) 2012-10-22
HRP20120667T2 (hr) 2012-11-30
RU2006133898A (ru) 2008-03-27
KR20070020411A (ko) 2007-02-21
CY1113084T1 (el) 2016-04-13
CY1107008T1 (el) 2012-09-26
BRPI0507984B1 (pt) 2018-07-03
BRPI0507984B8 (pt) 2023-03-21
AU2005214271A2 (en) 2005-09-01
ZA200607241B (en) 2008-04-30
TW200530227A (en) 2005-09-16
CY2012016I2 (el) 2016-12-14
SI1718641T1 (sl) 2007-12-31
DK1718641T3 (da) 2007-12-17
US7157584B2 (en) 2007-01-02
CY2012015I1 (el) 2016-12-14
WO2005080384A3 (en) 2006-09-28
MA28478B1 (fr) 2007-03-01
CY2012016I1 (el) 2016-12-14
AU2005214271B8 (en) 2011-03-03
PT1857457E (pt) 2009-09-23
CN101381366A (zh) 2009-03-11
EP1718641B1 (en) 2007-08-15
JP2009137974A (ja) 2009-06-25
IL177533A (en) 2010-12-30
US7875637B2 (en) 2011-01-25
MY142807A (en) 2011-01-14
HRP20120667T1 (en) 2012-09-30
HRP20090593T1 (hr) 2010-03-31
RS51137B (sr) 2010-10-31
TWI336702B (en) 2011-02-01
US20050187269A1 (en) 2005-08-25
BE2012C025I2 (pt) 2024-08-08
AU2005214271B2 (en) 2011-02-24
CN100503605C (zh) 2009-06-24
JP4256852B2 (ja) 2009-04-22
HRP20070510T3 (en) 2007-12-31
PL1718641T3 (pl) 2008-01-31
HK1115118A1 (en) 2008-11-21
JP2005272451A (ja) 2005-10-06
ATE440095T1 (de) 2009-09-15
AU2005214271A1 (en) 2005-09-01
SI1857457T1 (sl) 2010-01-29
RU2501798C2 (ru) 2013-12-20
EP1857457A2 (en) 2007-11-21
BR122012009489B8 (pt) 2023-03-21
NZ549755A (en) 2009-04-30
US20090270464A1 (en) 2009-10-29
PL1857457T3 (pl) 2009-12-31
BR122012009489B1 (pt) 2019-02-19
PT1718641E (pt) 2007-11-15
EP1857457B1 (en) 2009-08-19
NO2012017I1 (no) 2012-11-26
ME01089B (me) 2013-03-20
PL2119715T3 (pl) 2012-10-31
CY2012015I2 (el) 2016-12-14
ES2293552T3 (es) 2008-03-16
LU91962I2 (fr) 2012-05-21
US7572920B2 (en) 2009-08-11
ME01643B (me) 2010-05-07
NO20064251L (no) 2006-11-22
CN101381366B (zh) 2011-06-15
WO2005080384A9 (en) 2006-11-30
EP1718641A2 (en) 2006-11-08
PT2119715E (pt) 2012-09-03
RU2009115498A (ru) 2010-10-27
IL177533A0 (en) 2006-12-10
CA2557538A1 (en) 2005-09-01
WO2005080384A2 (en) 2005-09-01
CY1109610T1 (el) 2014-08-13
KR101080029B1 (ko) 2011-11-04
RS52376B (en) 2012-12-31
CN1946717A (zh) 2007-04-11

Similar Documents

Publication Publication Date Title
BRPI0507984A (pt) composto ou um sal do mesmo, processo para produzir um composto, medicamento, métodos para antagonizar angiotensina ii em um mamìfero, para melhorar a resistência de insulina em um mamìfero e para prevenir ou tratar doenças circulatórias em um mamìfero, e, uso do composto
WO2005013892A3 (en) Hydrolytically-resistant boron-containing therapeutics and methods of use
EA200900388A1 (ru) Бензоксазолы и оксазолопиридины, применимые в качестве ингибиторов киназ janus
NO20064201L (no) Glukopyranosylsubstituerte benzolderivater, medikamenter inneholdende slike forbindelser, deres anvendelse og fremstilling
PL1613315T3 (pl) Pochodne chinolino-2-onu do leczenia chorób dróg oddechowych
NO20076425L (no) Fremgangsmater for behandling av drug-resistent cancer
MY142830A (en) Propionic acid derivatives useful in the treatment of lipid disorders
TW200609227A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
BR0317705A (pt) Composto, formulação farmacêutica, uso de um composto, método de tratamento de doenças ou condições, e, processo para a preparação de compostos
DE50311898D1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
AU5584901A (en) Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
MXPA04005156A (es) Antagonistas del receptor de adenosina a2a.
BRPI0411098A (pt) benzofuranocarboxamidas, com atividade pi3k, como agentes terapêuticos
ATE412646T1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
TN2009000483A1 (fr) Derives de 7-alkynyl-1-8-naphthyridones, leur preparation et leur application en therapeutique
DK1483251T3 (da) C3-cyano-epothilon-derivater
DE502005008058D1 (de) Gesättigte und ungesättigte 3-pyridyl-benzocycloalkylmethyl-amine zur behandlung von schmerzen, depressionen und angstzuständen
DK1778680T3 (da) Spirocykliske cyclohexaderivater
MXPA03008635A (es) Compuestos de dihidropirimidina ciano sustituidos y su uso para tratar enfermedades.
BRPI0513513A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparar o mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, métodos para produzir um efeito inibitório de eg5 e um efeito anticáncer em um animal de sangue quente, e para tratar carcinomas em um animal de sangue quente
BRPI0518000A (pt) tetrahidroisoquinolinas aril- e heteroaril- substituìdas e uso das mesmas para bloquear a reabsorção de norepinefrina, dopamina e serotonina
NO20054361L (no) Benzensylfonamidderivater, fremgangsmate for fremstilling og anvendelse derav for behandlig av smerte
BR0315837A (pt) Derivados de amida de ácido heteroaril-hexanóico como agentes imunomoduladores
WO2008106125A3 (en) Deuterated derivatives of silodosin as alpha la-adrenoceptor antagonists
EP1627635A3 (en) Benzothiazolium compounds for use in methods of inhibiting NO production and TNF alpha and treating coronaviral infection

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B25C Requirement related to requested transfer of rights

Free format text: A FIM DE ATENDER A TRANSFERENCIA, REQUERIDA ATRAVES DA PETICAO NO 870200120247 DE 24/09/2020, E NECESSARIO APRESENTAR O DOCUMENTO DE CESSAO NOTARIZADO E COM APOSTILAMENTO OU LEGALIZACAO CONSULAR, ALEM DA GUIA DE CUMPRIMENTO DE EXIGENCIA.

B25A Requested transfer of rights approved
B25A Requested transfer of rights approved
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/02/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B15V Prolongation of time limit allowed
B25A Requested transfer of rights approved